Achaogen Inc represents values of innovation, dedication, and patient-centeredness. As a leading biopharmaceutical company, Achaogen Inc is committed to developing and commercializing innovative antibacterial treatments to address the urgent global health threats posed by multi-drug resistant infections. With a corporate philosophy centered around advancing the standard of care for patients, Achaogen Inc strives to provide effective and safe antibiotics that target bacteria resistant to traditional treatment options. By leveraging cutting-edge research and development technologies, Achaogen Inc aims to make a positive impact on public health by addressing the unmet medical needs of patients suffering from serious infections.

Achaogen Inc is primarily present in the United States, focusing on the development and commercialization of innovative antibacterial treatments.

Achaogen Inc. has achieved several significant milestones in its history. The company successfully developed ZEMDRI® (plazomicin), an antibiotic used for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis. In addition, Achaogen Inc. secured FDA approval for ZEMDRI® in June 2018, becoming the company's first commercialized product. The accomplishment showcased the company's capabilities in developing innovative therapies to combat serious infections. Achaogen Inc. also secured multiple grants and collaborations, including support from the Biomedical Advanced Research and Development Authority (BARDA) and partnerships with other healthcare organizations. These achievements reflect the company's commitment to addressing critical medical needs and advancing the field of antibiotic research and development.

Achaogen Inc is a biopharmaceutical company based in South San Francisco, California. Founded in 2002, the company specializes in the discovery, development, and commercialization of innovative antibacterial treatments. Achaogen Inc is dedicated to addressing the growing threat of antibiotic resistance by utilizing its expertise in research and development. With a focus on serious infections caused by multidrug-resistant bacteria, the company aims to provide patients with groundbreaking therapeutic options. Over the years, Achaogen Inc has made significant advancements in the field of antibacterial treatments, cementing its position as a leader in the industry.

The main competitors of Achaogen Inc in the market are pharmaceutical companies focused on the development and commercialization of antibiotics and antimicrobial agents. Some notable competitors include Merck & Co., Pfizer Inc., GlaxoSmithKline, Novartis AG, and Roche Holding AG. These companies, like Achaogen Inc, are actively engaged in the research, development, and commercialization of innovative therapies to combat antibiotic-resistant infections. They compete for market share and strive to address unmet medical needs in the field of infectious diseases.

Achaogen Inc is primarily active in the pharmaceutical industry.

The business model of Achaogen Inc revolves around developing and commercializing innovative antibacterial therapies for serious infections caused by multidrug-resistant bacteria. Achaogen Inc focuses on discovering and developing drugs that target bacterial pathogens resistant to existing antibiotics. The company aims to address the urgent need for new antibiotics through its research and development efforts. By leveraging its expertise in antibiotic drug discovery and development, Achaogen Inc strives to provide new treatment options for patients and healthcare providers combating drug-resistant infections.

De K/W-verhouding kan momenteel niet worden berekend voor Achaogen.

De KUV kan momenteel niet worden berekend voor Achaogen.

De AlleAktien Kwaliteitsscore voor Achaogen is 3/10.

De omzet kan momenteel niet worden berekend voor Achaogen.

De winst kan momenteel niet berekend worden voor Achaogen.

Achaogen Inc. is a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for the treatment of severe bacterial infections. The company was founded in 2002 and is headquartered in South San Francisco, California. Achaogen has a diverse portfolio of products, including Zemdri, the only approved intravenous antibiotic for the treatment of patients with complicated urinary tract infections (cUTI) when other antibiotics do not work. It is also a significant partner in public health and offers specialized consulting services for clinical microbiology and infection control. Achaogen's business model is focused on the discovery and development of antibiotics against antibiotic resistance and serious infectious diseases. The company aims to bring new antibiotics to market to meet the growing need for effective antibiotics that are effective against bacterial infections that have become resistant to conventional antibiotics. Achaogen uses a unique business model that focuses on three main areas: the discovery and development of novel antibiotics for MDR infections, the clinical development of antibiotics, and innovative services for microbiologists and infection control professionals. Overall, Achaogen's business model has proven successful, particularly in the face of advancing antibiotic resistance. The company understands the importance of continued research and development of antibiotics and is committed to providing new and innovative solutions for severe bacterial infections. Through its unique research and development strategy, clinical development, and comprehensive services, Achaogen Inc. has a strong position in the field of antibiotic research and development.

Achaogen keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Achaogen of het bedrijf keert geen dividend uit.

De ISIN van Achaogen is US0044491043.

Het WKN van Achaogen is A1XFMJ.

De ticker van Achaogen is AKAOQ.

Binnen de laatste 12 maanden betaalde Achaogen een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Achaogen naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Achaogen is momenteel .

Achaogen betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Achaogen betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Achaogen wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Achaogen van 29-11-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 29-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 29-11-2024.

In het jaar 2023 heeft Achaogen 0 USD aan dividenden uitgekeerd.

De dividenden van Achaogen worden in USD uitgekeerd.